Australia vs China: Hepatitis B surface antigen (HBsAg) prevalence
Australia
0.1%
in 2024
China
0.1%
in 2024
Australia rank
101st
China rank
101st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Australia
- China
How they compare
Australia currently reports 0.1% against 0.1% in China, a difference of 0.0%.
Across all 10 years both countries report, China has been ahead every year.
Australia ranks 101st and China ranks 101st of 194 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Australia | China | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | China |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Australia or China?
- Australia, at 0.1% against 0.1% in China as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Australia and China?
- 0.0%, with Australia ahead.
- How many years of comparable data are there for Australia and China?
- 10 years are reported by both, from 2015 to 2024.
- How do Australia and China rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Australia ranks 101st and China ranks 101st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.